Nabi Biopharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Nabi Biopharmacetuicals is a drug development company in Rockville, Maryland.

Its principle product is NicVAX (also known as 3′AmNic-rEPA), a nicotine conjugate vaccine intended to reduce physical addiction to nicotine.

The drug was developed with help from the U.S. National Institute of Drug Abuse, and showed promise in early studies,[1][2] however, two successive phase III trials of the drug in 2009 and 2011 failed.[3][4]

On Thursday, November 8, 2012 the business combination of Nabi Biopharmaceuticals and Biota Holdings Limited became effective to create Biota Pharmaceuticals, Inc. (NASDAQ: BOTA)

External links[edit]

Biota Pharmaceuticals, Inc.

References[edit]

  1. ^ Barbara Shine (October 2000). "Nicotine Vaccine Moves Toward Clinical Trials". National Institute on Drug Abuse. Archived from the original on 2006-08-10. Retrieved 2006-09-19. 
  2. ^ Thomas E. Rathjen (2006-10-12). "Nabi Biopharmaceuticals Completes Enrollment in NicVAX Phase IIB 'Proof-of-Concept' Clinical Trial". Nabi Biopharmeceuticals. Retrieved 2006-12-23. 
  3. ^ "Nabi Biopharmaceuticals Initiates Pivotal Phase III Study for NicVAX as an Aid to Smoking Cessation and Long-term Abstinence". Nabi Biopharmaceuticals. November 3, 2009. 
  4. ^ [1]